Introduction
============

It has long been appreciated that the metabolism of normal and malignant cells can significantly differ ([@ref-36], [@ref-36]). Measuring the cellular metabolomic profiles can therefore provide a "snapshot" of the degree of oncogenic malignancy in cancer cells ([@ref-16], [@ref-16]). One particularly important technique that can measure metabolomic profiles is nuclear magnetic resonance (NMR). NMR is a noninvasive method that can provide highly reproducible and quantitative metabolomic information and has been previously used to detect metabolic fingerprints from a variety of oncogenic pathways ([@ref-24], [@ref-24]; [@ref-34], [@ref-34]).

One of the earliest applications of cellular NMR metabolomics has been to look for biomarkers associated with activation of the RAS oncogene ([@ref-1], [@ref-1]; [@ref-32], [@ref-32]). The RAS oncogene, which can exist in either of the HRAS, KRAS, or NRAS isoforms, is found mutated in approximately 30% of all human cancers and produces aggressive, treatment resistant tumors ([@ref-12], [@ref-12]). Of the three major isoforms, KRAS is found to be the most commonly mutated in human tumors. NRAS is also found activated in certain tumor types such as melanoma, whereas HRAS mutations are rarely found in human cancers ([@ref-5], [@ref-5]). The three isoforms, which differ in their membrane-targeting domain, were historically considered to be redundant in their function ([@ref-6], [@ref-6]). However, a number of studies have shown that the three isoforms are functionally different ([@ref-21], [@ref-21]; [@ref-35], [@ref-35]; [@ref-38], [@ref-38]) with tumors sustaining distinct oncogenic versions of RAS showing different progression characteristics ([@ref-28], [@ref-28]; [@ref-37], [@ref-37]). Accordingly, high-throughput noninvasive means of detecting RAS signatures from tumor cells are likely to aid in effective diagnosis and design of treatment regimens that target RAS-specific pathways ([@ref-9], [@ref-9]; [@ref-27], [@ref-27]). However to our knowledge, differences in the metabolomic profiles between normal cells and cells transformed with either of oncogenic HRAS, KRAS, or NRAS have not been previously investigated. Anticipating that there will be robust differences between untransformed and RAS-transformed cells, we employed a cell culture system to validate the NMR methodology described in this study.

Specifically, we analyzed BEAS2B immortalized lung epithelial cells stably transformed with either an empty retroviral vector or with either one of the activated versions of the RAS isoforms, HRAS, KRAS and NRAS, as a proof-of-principle system to determine whether ^1^H NMR-based metabolomics could be used to identify unique metabolomic signatures between the RAS-transformed and control cells as well as among the different RAS isoform-transformed cell lines. The advantage of this cell culture system is the isogenic background among the four cell lines as well as the ability to generate the requisite numbers of stably transformed cells for consistent NMR characterization. Our NMR characterization of the metabolomic profiles indicated that each RAS isoform possesses a distinct metabolomic signature that has bearing on its observed cell-physiologic transformative effects.

Materials and Methods
=====================

DNA constructs and viral transduction
-------------------------------------

The retroviral pBABE KRASV12, HRASV12 and NRASQ61 DNA constructs were obtained from Addgene. Stable transduction of the pBABE empty vector and the RAS constructs into BEAS2B cells was performed as previously described ([@ref-30], [@ref-30]). Transduced cells were selected in 2.5 µg/ml puromycin-containing complete culture media for a minimum period of 5--7 days (corresponding to the time taken for untransduced BEAS2B cells to die completely in selection media). Oncoprotein overexpression relative to the control cells was verified via Western blotting as previously described ([@ref-30], [@ref-30]).

Cell culture
------------

BEAS2B cells were obtained from the American Type Culture Collection. All cells were grown at 37 °C in 21% oxygen and 5% CO~2~. BEAS2B cells and their derivative lines were maintained in DMEM:F12 complete base media supplemented with 10% fetal bovine serum and 100 units/ml penicillin-streptomycin. All cell culture reagents were obtained from Life Technologies. For each cell line, ten biological replicates were generated by initially seeding ten different 15 cm dishes (Nunclon) with an initial plating of approximately 1 × 10^6^ cells for the control cells, 1.5 × 10^6^ cells for the HRAS- and KRAS-transformed cells, and 2 × 10^6^ for the NRAS-transformed cells (differences in the initial seedings were used to compensate for differences in cellular growth rates so that by the end of the growth period, approximately the same number of cells for each cell line was obtained). In total, all forty plates were seeded at approximately the same time and were allowed to proliferate for a period of four days with the media changed every 48 h. After four days, the cells were trypsinized for approximately two minutes and counted using a Moxi automatic cell counter (VWR) with size parameters adjusted to exclude apoptotic cells. The average final cell counts were (1.107 ± 0.050) × 10^7^ cells per control sample, and (1.558 ± 0.291) × 10^7^, (1.486 ± 0.124) × 10^7^, and (1.613 ± 0.156) × 10^7^ cells per HRAS-, KRAS-, and NRAS-transformed sample, respectively. This corresponded to an average population doubling time of 27.68 h for the control cells and 28.43 h, 29.02 h, and 31.89 h for the HRAS-, KRAS-, and NRAS-transformed cells, respectively. After counting, the cells were pelleted at 1,500 rpm for 5 min at 4 °C with the pellets immediately snap-frozen in liquid nitrogen and stored at --80 °C.

Metabolite extraction
---------------------

The extraction of hydrophilic metabolites from cell pellets was performed using previously established procedures ([@ref-15], [@ref-15]). Briefly, cell pellets in a 1.5 ml Eppendorf tubes were resuspended by adding 500 µl of a 2:1 (*v*∕*v*) ice-cold solution of methanol (Sigma-Aldrich) and chloroform (Sigma-Aldrich) followed by 3--5 min of vortexing and manual mixing for at least 10 min until a clear solution was obtained. Next, 250 µl of ice-cold chloroform and 250 µl of ice-cold water were each added to the sample, which was then vortexed for 5--7 min to yield a cloudy solution. The sample was sonicated at room temperature for ten minutes followed by centrifugation at 13,000 rpm for 5 min at 4 °C in order to yield three layers. The hydrophilic layer was transferred to a fresh Eppendorf tube followed by bubbling with nitrogen gas (Airgas) to remove any residual methanol. The samples were placed under a high speed vacuum concentrator at room temperature until dried, and the dried hydrophilic layer was stored in a --80 °C freezer until needed.

NMR sample preparation, acquisition, and processing
---------------------------------------------------

The dried hydrophilic layer was resuspended in 400 µl of deuterated PBS at pH = 7.6 that was prepared as previously reported ([@ref-33], [@ref-33]). The pH of each sample was adjusted to 7.6 by the addition of either dilute HCl or NaOH as needed to ensure that each metabolite appeared at the same chemical shift in all samples. In each sample, 0.5 µl of a 0.1 M aqueous solution of DSS (Sigma Aldrich) was added for chemical shift referencing. After vortexing, each sample was transferred into a 5 mm NMR tube.

![NOESY pulse sequence, Western Blots, and Representative Spectra.\
(A) The 1D NOESY with presaturation pulse sequence. (B) Western blots depicting the control and oncogenic HRAS-, KRAS-, and NRAS-transformed cells. (C) Representative spectra obtained from the 1D NOESY sequence applied to samples made from the control and HRAS-, NRAS-, and KRAS-transformed cells. The spectra were normalized so that the DSS resonance at *δ* = 0 ppm had the same intensity in all spectra *for display purposes only*. The spectral region for the water resonance is not shown, and certain metabolite resonances are labeled using the codes 1--21 given in [Table 1](#table-1){ref-type="table"}.](peerj-04-2104-g001){#fig-1}
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###### Table of chemical shifts and splitting patterns for metabolites identified by NMR.

List of identified metabolites from the hydrophilic layer, with their corresponding CHEBID, chemical shifts (ppm) and splitting patterns (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublet of doublets; bs, broad singlet; bd, broad doublet; bt, broad triplet) used in the Chenomx analysis of the ^1^H spectra. The labels 1--21 are for those metabolites that exhibited a significant difference (adjusted *p*-values ≤0.01) between at least two cell types in either their "effective" NMR metabolite fraction, $\documentclass[12pt]{minimal}
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  Metabolite \[CHEBI ID\]                                                        ^1^H chemical shifts (ppm) and multiplicity
  ------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Acetate \[15366\]                                                              1.90(s)
  Alanine, **1** \[16977\]                                                       1.47(d), 3.77(q)
  Beta-alanine, **2** \[16958\]                                                  2.54(t), 3.16(t)
  Arginine \[16467\]                                                             1.64(m), 1.72(m), 1.88(m), 1.92(m), 3.42(t), 3.75(t)
  A[X]{.ul}P \[15422, 16027, 16761\]                                             4.22(m), 4.29(m), 4.39(m), 4.57(t), 4.8(m), 6.14(d), 8.26(s), 8.52(bs)
  Aspartate, **3** \[17053\]                                                     2.67(dd)[^a^](#table-1fn1){ref-type="fn"}
  Choline, **4** \[15354\]                                                       3.19(s), 3.51(m), 4.06(m)
  Choline alfoscerate, **5** \[16870\]                                           2.14(s), 3.22(bs), 3.75(m), 4.54(m)
  Citrate \[30769\]                                                              2.51(d)[^a^](#table-1fn1){ref-type="fn"}, 2.68(d)[^a^](#table-1fn1){ref-type="fn"}
  Creatine, **6** \[16919\]                                                      3.02(s), 3.92(s)
  Creatine phosphate, **7** \[17287\]                                            3.03(s), 3.94(s)
  Formate \[30751\]                                                              8.44(s)
  Fumarate, **8** \[18012\]                                                      6.51(s)
  Glutamate \[16015\]                                                            2.04(dddd), 2.12(dddd), 2.31(ddd)[^a^](#table-1fn1){ref-type="fn"}, 2.36(ddd)[^a^](#table-1fn1){ref-type="fn"}, 3.74(dd)
  Glutamine, **9**\[18050\]                                                      2.10(m), 2.14(m), 2.42(m), 2.47(m), 3.76(t)
  Glutathione \[16856\]                                                          2.14(m), 2.17(m), 2.53(m), 2.57(m), 2.93(dd)[^a^](#table-1fn1){ref-type="fn"}, 2.97(dd)[^a^](#table-1fn1){ref-type="fn"}, 3.75(dd)[^a^](#table-1fn1){ref-type="fn"}, 3.77(dd)[^a^](#table-1fn1){ref-type="fn"}, 3.79(dd)[^a^](#table-1fn1){ref-type="fn"}, 4.55(bt)
  Glycine \[15428\]                                                              3.55(s)
  Isocitrate \[151\]                                                             3.02(s), 3.94(s)
  Isoleucine \[17191\]                                                           0.93(t), 0.99(d), 1.25(m), 1.46(m), 1.97(m), 3.66(d)
  Lactate, **10** \[422\]                                                        1.32(d), 4.10(q)
  Leucine, **11** \[15603\]                                                      0.94(d), 0.96(d), 1.67(m), 1.70(m), 1.73(m), 3.70(m)
  Malate \[6650\]                                                                2.35(dd), 2.66(dd), 4.29(bd)
  Myo-inositol, **12** \[17268\]                                                 3.26(t), 3.52(dd), 3.61(dd)[^a^](#table-1fn1){ref-type="fn"}, 4.05(t)
  N-acetylaspartate, **13** \[21547\]                                            2.00(s), 2.48(dd), 2.68(dd), 4.38(ddd)
  N-acetylcysteine, **14** \[28939\]                                             2.07(s), 2.90(dd)[^a^](#table-1fn1){ref-type="fn"}, 2.93(dd)[^a^](#table-1fn1){ref-type="fn"}, 4.37(m)
  N-acety[Y]{.ul}[^c^](#table-1fn3){ref-type="fn"} \[17533\]                     1.91(m), 2.03(s), 2.10(m), 2.30(m), 2.33(m), 4.15(m)
  \[NADZ\][^d^](#table-1fn4){ref-type="fn"} \[15846, 16908\]                     8.165(s), 8.41(s), 9.33(s)
  \[NADPZ\][^d^](#table-1fn4){ref-type="fn"} \[16474, 18009\]                    8.14(s), 8.41(s), 9.29(s)
  Phenylalanine, **15** \[17295\]                                                3.11(dd), 3.37(dd), 3.98(dd), 7.31(d)[^a^](#table-1fn1){ref-type="fn"}, 7.36(m), 7.41(m)
  Phosphocholine, **16** \[18132\]                                               3.21(bs), 3.58(m), 4.15(m)
  Proline, **17** \[17203\]                                                      1.98(m), 2.03(m), 2.06(m), 2.34(m), 3.33(m), 3.41(m), 4.12(dd)
  Pyruvate \[32816\]                                                             2.36(s)
  Succinate \[15741\]                                                            2.39(s)
  Taurine, **18** \[15891\]                                                      3.25(t), 3.41(dd)
  Tyrosine, **19** \[17895\]                                                     3.04(dd), 3.18(dd), 3.93(dd), 6.88(d)[^a^](#table-1fn1){ref-type="fn"}, 7.18(d)[^a^](#table-1fn1){ref-type="fn"}
  UDP-[X]{.ul}[^b^](#table-1fn2){ref-type="fn"}, **20**\[17200, 18066, 18307\]   3.44(t), 3.53(td), 3.76(t), 3.78(dd), 3.86(m), 3.89(m), 4.19(ddd)[^a^](#table-1fn1){ref-type="fn"}, 4.24(ddd)[^a^](#table-1fn1){ref-type="fn"}, 4.27(m), 4.36(m), 4.37(m), 5.59(dd), 5.96(d), 5.98(bd), 7.94(d)
  Valine, **21** \[16414\]                                                       0.98(d), 1.03(d), 2.26(hd), 3.60(d)
  DSS                                                                            0.00(s), 0.63(m), 1.76(m), 2.91(m)

**Notes.**

Multiplet with second-order couplings.

For UDP-[X]{.ul} can be UDP-galactose, UDP-glucose, or UDP-glucoranate.

For N-acetyl[Y]{.ul}, the resonances used in the analysis stand for N-acetylglutamate, N-acetylglycine, and/or (and most likely) N-acetylglutamine.

Only the listed resonances were used in the analysis of \[NAD[Z]{.ul}\] {\[NADH\] and/or \[NAD^+^\]}, and \[NADP[Z]{.ul}\] {\[NADPH\] and/or \[NADP^+^\]}.

The ^1^H NMR spectra were acquired on a 500 MHz Bruker Avance spectrometer (operating at 500.13 MHz for ^1^H observation) equipped with a 5 mm TCI 500S2 H-C/N-D-05 Z cryoprobe head at 298 K. Each sample was tuned and matched, reshimmed, and the 90°pulse length was recalibrated (90°pulse lengths ranged between 10 and 12 µs). The ^1^H NMR spectra were acquired using a standard Bruker 1D NOESY pulse program with water presaturation and spoiler gradients applied during the relaxation delay, "noesygppr1d.2" as shown in [Fig. 1A](#fig-1){ref-type="fig"}. This pulse sequence provides good solvent suppression without rolling baselines ([@ref-2], [@ref-2]; [@ref-23], [@ref-23]). The following experimental parameters were used in all measurements: sweep width of 10.33 kHz, 65 K acquisition points, a 2 s recycle delay during which a 93 Hz water presaturation pulse was applied, *τ*~*mix*~ = 101.2 ms, *θ* = 7.5°--9°, and 256 scans were acquired for each sample. Half-sine shaped pulsed field gradients of duration 1 s with maximum gradient strengths of G1 = 24 G/cm and G2 = --23.7 G/cm were used in [Fig. 1A](#fig-1){ref-type="fig"} along with a 200 µs gradient stabilization delay placed after each gradient pulse. After acquisition, all FIDs were imported into the Chenomx NMR Suite Profiler (version 7.6., Chenomx Inc., Edmonton, Canada). The data were Fourier transformed after multiplication by an exponential window function with a line broadening of 0.5 Hz, and the spectra were manually phase corrected and baseline adjusted using a cubic-spine function. From the initial set of ten biological replicates for each cell line, only 8 of the control, 7 of the HRAS, 9 of the KRAS, and all 10 of the NRAS samples provided measureable NMR signal from resonances other than the solvent peak. Therefore, the results presented in this work represent data obtained from those *N*~*S*~ = 8 biological replicates of the control cells, and those *N*~*S*~ = 7, *N*~*S*~ = 9, and *N*~*S*~ = 10 biological replicates of the HRAS-, KRAS-, and NRAS-transformed cells.

The Chenomx NMR Suite Profiler was used to identify metabolites by fitting compound signatures from the provided NMR spectral library. In total, 37 metabolites were identified by NMR. The effective NMR metabolite concentration in each sample, *S*~*metabolite*~, was calculated using the Chenomx NMR Suite Profiler by determining the heights of the compound signatures that best fit the sample spectra with the effective concentration of the internal DSS standard being set to *S*~*DSS*~ = 0.1248 mM, which was the actual DSS concentration in each sample. The table of identified metabolites and their signals was then exported and saved in an Excel worksheet.

Statistical analysis
--------------------

The "effective" NMR cellular content for metabolite *α* (moles/cell) taken from the *s*th biological replicate of a given cell type, $\documentclass[12pt]{minimal}
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An ANOVA test, implemented using the MATLAB function "anova1" available in MATLAB's Statistics toolbox, was first used to test the hypotheses that $\documentclass[12pt]{minimal}
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Results and Discussion
======================

Generation of isogenic cell lines for the study
-----------------------------------------------

The results of immunoblotting total protein lysates from the four cell types against the various RAS isoforms are shown in [Fig. 1B](#fig-1){ref-type="fig"}. Western blotting with antibodies against HRAS (first lane), KRAS (second lane) and NRAS (third lane) confirmed that the cells expressed the appropriate RAS isoforms. Uniformity of loading was also confirmed by immunoblotting against GAPDH, a housekeeping gene, as shown in the bottom lane of [Fig. 1B](#fig-1){ref-type="fig"}. Previous characterizations of these cell lines have also confirmed that the introduction of the RAS oncogene confers soft agar colony growth in these cells, which is indicative of oncogenic transformation ([@ref-31], [@ref-31]; [@ref-29], [@ref-29]; [@ref-13], [@ref-13]).

![Loadings and score plots for effective NMR metabolite fractions.\
PCA of the effective NMR metabolite fractions, *x*~*metabolite*~ in [Eq. (2)](#eqn-2){ref-type="disp-formula"}, and glutamate normalized signals, *ξ*~*metabolite*,*glutamate*~ in [Eq. (3)](#eqn-3){ref-type="disp-formula"}, for (asterisks) control and (diamonds) HRAS-, (circles) KRAS-, and (squares) NRAS-transformed cells. Loading plots for *x*~*metabolite*~\[(A) PC1 (75.1%) and PC2 (16.3%)\] and *ξ*~*metabolite*,*glutamate*~ \[(C) PC1 (77.9%) and PC2 (17.0%)\] are shown. The identities of certain metabolites are denoted by the labels given in [Table 1](#table-1){ref-type="table"}. Score plots of PC2 versus PC1 of centered data with the corresponding 99% confidence ellipses ([@ref-19], [@ref-19]) are shown for both the (B) *x*~*metabolite*~ and (D) *ξ*~*metabolite*,*glutamate*~ data. The results in this figure are from *N*~*S*~ = 8 biological replicates of the control cells and *N*~*S*~ = 7, *N*~*S*~ = 9, and *N*~*S*~ = 10 biological replicates of the HRAS-, KRAS-, and NRAS-transformed cells, respectively.](peerj-04-2104-g002){#fig-2}

NMR-based characterization and PCA of metabolomic profiles
----------------------------------------------------------

Representative spectra taken from a single biological replicate of the control and HRAS-, KRAS-, and NRAS-transformed cells are shown in [Fig. 1C](#fig-1){ref-type="fig"}, where the spectra were normalized so that the DSS resonance at *δ* = 0 ppm had the same intensity in all spectra *for display purposes only*. Certain key metabolites are labeled using the codes, 1--21, given in [Table 1](#table-1){ref-type="table"}.

The loadings of PC1 (score of 75.1%) and PC2 (score of 16.3%) from a PCA of $\documentclass[12pt]{minimal}
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}{}${x}_{metabolite}^{Cell\hspace*{2.5pt}type}$\end{document}$ are shown in [Fig. 2A](#fig-2){ref-type="fig"}, where some of the components of both PC1 and PC2 are labeled using the codes given in [Table 1](#table-1){ref-type="table"}. In [Fig. 2B](#fig-2){ref-type="fig"}, a score plot of PC1 vs. PC2, with the corresponding 99% confidence ellipses ([@ref-19], [@ref-19]) drawn for convenience, shows non-overlapping grouping between the control and the RAS-transformed cells. Similar results were also observed when performing a PCA of $\documentclass[12pt]{minimal}
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Non-overlapping groupings at the 99% confidence level between *all* cell lines were found by plotting $\documentclass[12pt]{minimal}
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}{}${x}_{phosphocholine}^{Cell\hspace*{2.5pt}type}$\end{document}$ as shown in [Fig. 3A](#fig-3){ref-type="fig"}, which were mainly due to differences in the phosphocholine levels between cell types ([Fig. 4](#fig-4){ref-type="fig"}). Likewise, non-overlapping groupings between *all* cell lines, this time at a slightly lower confidence level of 97.5%, were also found by plotting $\documentclass[12pt]{minimal}
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Of the 37 metabolites identified by NMR, an ANOVA analysis indicated that 18 metabolites had a significant (adjusted *p*-values with *p* ≤ 0.01) difference in their "effective" NMR metabolite fraction (*x*~*α*~ in [Eq. (2)](#eqn-2){ref-type="disp-formula"}) between at least two of the four cell types. Box plots of $\documentclass[12pt]{minimal}
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![Groupings observed for both the lactate vs. phosphocholine NMR metabolite fractions and glutamate normalized signals.\
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![Box plots of the NMR metabolite fractions identified by ANOVA analysis.\
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![Box plots of the glutamate normalized signals identified by ANOVA analysis.\
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###### 99% confidence intervals for relative fold change in the ratio of actual cellular metabolite to glutamate content between cell types.

99% confidence intervals (CIs) for the relative fold change in glutmate normalized signals between cell lines calculated using Fieller's method ([@ref-25], [@ref-25]) in [Eq. (5)](#eqn-5){ref-type="disp-formula"}. The lower and upper limits of the 99% CIs are denoted by subscripts that bracket the middle of the CI interval ([@ref-22], [@ref-22]). The abbreviation, n.s., indicates those cases when there was no significant statistical difference in $\documentclass[12pt]{minimal}
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}{}$ \left\langle {\xi }_{metabolite,glutamate} \right\rangle $\end{document}$ found between cell lines from post-hoc testing using the BY algorithm ([@ref-3], [@ref-3]) at a false discovery rate of 0.01. The 99% CIs for the relative fold changes in the cellular fumarate to glutamate content in all RAS-transformed cells relative to control cells and in the cellular tyrosine to glutamate content in HRAS-transformed cells relative to control cells could not be calculated due to the small signals and large scatter of fumarate and tyrosine observed in the control cells (which gave *g* \> 1 in [Eq. (5)](#eqn-5){ref-type="disp-formula"}).
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  Aspartate             n.s.                                                                                                                                          ~0.15~0.36~0.56~                                                                                                                              n.s.
  Choline alfoscerate   n.s.                                                                                                                                          ~0.22~0.44~0.65~                                                                                                                              n.s.
  Myo-inositol          n.s.                                                                                                                                          ~1.14~1.34~1.55~                                                                                                                              n.s.
  Phosphocholine        ~0.58~0.67~0.76~                                                                                                                              ~1.99~2.23~2.47~                                                                                                                              ~1.27~1.48~1.69~
  Taurine               n.s.                                                                                                                                          ~1.23~1.57~1.91~                                                                                                                              ~1.19~1.61~2.04~
  UDP-[X]{.ul}          ~1.44~1.80~2.16~                                                                                                                              n.s.                                                                                                                                          n.s.

Similarly, an ANOVA analysis of the glutamate normalized metabolite content indicated that 16 metabolites had a significant (adjusted *p*-values with *p* ≤ 0.01) difference in $\documentclass[12pt]{minimal}
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}{}$ \left\langle {\xi }_{tyrosine,glutamate} \right\rangle $\end{document}$ were observed ([Fig. 5](#fig-5){ref-type="fig"} and [Table S2](#supp-2){ref-type="supplementary-material"}), the 99% CIs for the relative fold change in the cellular fumarate to glutamate content and the cellular tyrosine to glutamate content could not be calculated due to the small signals and large scatter observed for both tyrosine and fumarate in the control cells (which gave *g* \> 1 in [Eq. (5)](#eqn-5){ref-type="disp-formula"}).

NMR-based identification of metabolite differences among the transformed and control cell lines reflect RAS-driven physiologic alterations
------------------------------------------------------------------------------------------------------------------------------------------

Due to the Warburg effect ([@ref-36], [@ref-36]), it is well known that oncogenic transformed cells undergo aerobic glycolysis as opposed to oxidative phosphorylation ([@ref-7], [@ref-7]). To establish the validity of our data against known metabolic changes, we assessed how differences in the NMR signals from lactate and alanine, two major byproducts of glycolytic metabolism ([@ref-8], [@ref-8]), varied among the different cell lines. The lactate NMR signal was the largest NMR signal observed in all cell lines ([Fig. 4](#fig-4){ref-type="fig"}), and lactate was also the largest component to PC1 in the PCA analyses of both *x*~*metabolite*~ and *ξ*~*metabolite*,*glutamate*~ in [Fig. 2](#fig-2){ref-type="fig"}. In fact, $\documentclass[12pt]{minimal}
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}{}${x}_{lactate}^{Control}$\end{document}$ ([Fig. 4](#fig-4){ref-type="fig"} and [Table S1](#supp-1){ref-type="supplementary-material"}). The cellular alanine to glutamate content was found to be elevated between 50%--75% in KRAS- and NRAS-transformed cells relative to the control cells ([Table 2](#table-2){ref-type="table"}), which is consistent with the reported phenotype of increased aerobic glycolysis in oncogenic RAS-transformed cells ([@ref-18], [@ref-18]), although we should point out that our study provides only a steady-state snapshot of the metabolic profile.

The cellular UDP-[X]{.ul} (i.e., UDP-glucose, UDP-galactose, and/or UDP-glucourinate), which are important molecules in glucose metabolism and in the formation of cellular polysaccharides ([@ref-4], [@ref-4]), to glutamate content was elevated between a factor of 1.69--2.94 in the RAS-transformed cells lines relative to the control cells ([Table 2](#table-2){ref-type="table"}). Likewise, the cellular N-acetylcysteine, a thiolic antioxidant ([@ref-26], [@ref-26]), to glutamate content was also elevated in all RAS-transformed cells relative to control cells ([Fig. 5](#fig-5){ref-type="fig"}) with statistically significant differences occurring for the KRAS- and NRAS-transformed cells, where $\documentclass[12pt]{minimal}
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}{}$ \frac{{C}_{NAC}}{{\hspace*{2.5pt}C}_{glutamate}} $\end{document}$ was 4.11 and 5.34 times larger relative to control cells, respectively ([Table 2](#table-2){ref-type="table"}). The elevated levels of N-acetylcysteine in RAS-transformed cells is a significant finding given that RAS-transformed cells are known to exhibit elevated redox protective mechanisms ([@ref-39], [@ref-39]).

The metabolomic signatures of two cellular osmolytes, taurine and myo-inositol, also showed significant differences between the RAS-transformed and control cells. The cellular taurine to glutamate content and the cellular myo-inositol to glutamate content were between 50--66% and 32--45% smaller in all RAS-transformed cells relative to the control cells, respectively ([Table 2](#table-2){ref-type="table"}). As osmolytes regulate the apoptotic cell death pathway ([@ref-20], [@ref-20]), the functional relevance of the lower values of $\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym} 
\usepackage{amsfonts} 
\usepackage{amssymb} 
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$ \frac{{C}_{myo-inositol}}{{\hspace*{2.5pt}C}_{glutamate}} $\end{document}$ and $\documentclass[12pt]{minimal}
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}{}$ \frac{{C}_{taurine}}{{\hspace*{2.5pt}C}_{glutamate}} $\end{document}$ observed in RAS-transformed cells may be related to their relative resistance to stress-induced programmed cell death.

An unexpected result from our study was the cellular phosphocholine to glutamate levels. Choline metabolism is an important component in lipid biogenesis ([@ref-14], [@ref-14]). The cellular phosphocholine to glutamate content in our study was between 60--82% smaller in the RAS-transformed cells relative to the control cells, and statistically significant differences among the RAS-transformed cells were also observed ([Fig. 5](#fig-5){ref-type="fig"} and [Table S2](#supp-2){ref-type="supplementary-material"}). Similarly, the cellular choline to glutamate content was around 1.78 times larger in the KRAS- and NRAS-transformed cells relative to the control cells ([Table 2](#table-2){ref-type="table"}). Although there are reports indicating phosphocholine levels correlate with elevated malignancy ([@ref-1], [@ref-1]; [@ref-32], [@ref-32]), exceptions in the published literature suggest that this conclusion may be specific to the RAS isoform and cell type being studied ([@ref-11], [@ref-11]).

We have demonstrated in this work that ^1^H NMR can be used to identify unique metabolomic signatures between BEAS-2B immortalized lung epithelial cells and those transformed with the isoforms of the RAS oncogene as well as among the three RAS isoforms. Collectively, our results suggest that measuring cellular metabolomic profiles can help in distinguishing between normal and RAS-transformed cells along with potentially distinguishing among cancer cells expressing different RAS isoforms. In the future, these results may aid in the development of potential screening technology to determine particular cancer treatment regimens.
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###### Adjusted *p*-values from the Benjamini--Yekutieli multiple comparison testing on the NMR metabolite fractions for those metabolites identified by ANOVA analysis ([Fig. 4](#fig-4){ref-type="fig"})

The adjusted *p*-values from post-hoc/multiple comparison testing of the effective NMR metabolite fractions (([1](#eqn-1){ref-type="disp-formula"}) in the main text) using the Benjamini Yekutieli (BY) algorithm ([@ref-3], [@ref-3]) with a false discover rate of 0.01. Only those metabolites where an ANOVA analysis indicated that the average value of NMR metabolite fraction was different between at least two of the four cell types are listed. Significant differences (adjusted *p*-values ≤0.01) are bolded in red.

###### 

Click here for additional data file.
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###### Adjusted *p*-values from the Benjamini--Yekutieli multiple comparison testing on the glutamate normalized signals for those metabolites identified by ANOVA analysis ([Fig. 5](#fig-5){ref-type="fig"})

The adjusted *p*-values from post-hoc/multiple comparison testing of the glutamate normalized signals, ([Eq. (3)](#eqn-3){ref-type="disp-formula"} in the main text) using the Benjamini Yekutieli (BY) algorithm ([@ref-3], [@ref-3]) with a false discover rate of 0.01. Only those metabolites where an ANOVA analysis indicated that the average value of glutatmate normalized signal was different between at least two of the four cell types are listed. Significant differences (adjusted *p*-values ≤0.01) are bolded in red.

###### 

Click here for additional data file.
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###### Box plots for those metabolites where the average NMR metabolite fraction was not significantly different between at least two cell types

Box plots of NMR metabolite fraction for those 19 metabolites where an ANOVA test did not identify a significant difference in the average NMR metabolite fraction between at least two of the four cell types.
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Click here for additional data file.
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###### Box plots for those metabolites where the average glutamate normalized signal was not significantly different between at least two cell types

Box plots of the glutamate normalized signals for those 20 metabolites where an ANOVA test did not identify a significant difference in the average glutamate normalized signal between at least two of the four cell types.

###### 

Click here for additional data file.
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###### Matlab files and commands

Matlab files for Benjamini-Hochberg multiple comparison testing (fdr_bh.m), calculating confidence intervals using Fieller's theorem (fieller.m), and for calculating confidence ellipses (ellipso.m and plot_ellipse.m). The file MetabolomicsPeerJMatlabCommands.m gives the commands used in statistical analysis of metabolomics data.
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Click here for additional data file.
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###### Chenomx data for 37 metabolites + DSS

NMR sample metabolite concentration for *N* = 8, *N* = 10, *N* = 9, and *N* = 7 Biological replicates for the control (P) cells and NRAS-, KRAS-, and HRAS-transformed cells along with moxi cell counts for cells used to make those particular samples.

###### 

Click here for additional data file.
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